explore -WSS

explore

author：hotspot 2025-09-06 03:16:52 - browse：885

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Can medical device makers keep up in the race to treat obesity?

WSS

J&J expands global access to TB drug amid advocacy campaign

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Can medical device makers keep up in the race to treat obesity?

Argenx drug significantly slows progression of nerve disorder

A public health expert passes on football's full body collisions for youths

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

focus

explore

knowledge

Jerome Adams on the need for new antivirals for Covid

Reanimated hearts work just as well for transplants, study finds

How one medical school became remarkably diverse

Europe sees delivery challenges ahead on Alzheimer's therapies

How one medical school became remarkably diverse

Senate panel passes drug pricing bills, but drops one PBM reform

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Woman gored by Bison at Yellowstone

Activists slam private health insurers over coverage restrictions

The new HIV moral panic

hotspot

Can medical device makers keep up in the race to treat obesity?

Mike Pence clashes with Tucker Carlson in Iowa

Living organ donors deserve priority status for transplants

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Senate panel passes drug pricing bills, but drops one PBM reform

Involuntary treatment for addiction doesn't work

explore

leisure time

explore

leisure time